MSFT 447.67 -0.4691% AAPL 208.14 0.3133% NVDA 118.11 -6.684% GOOGL 179.22 -0.2282% GOOG 180.79 0.294% AMZN 185.57 -1.8564% META 498.91 0.8347% AVGO 1592.21 -4.0045% TSLA 182.58 -0.235% TSM 167.81 -3.5353% LLY 890.11 0.7048% V 276.3 0.3924% JPM 198.88 1.3143% UNH 489.98 1.5313% NVO 142.28 0.2254% WMT 68.9 1.4578% LVMUY 155.41 1.3169% XOM 114.04 2.9614% LVMHF 780.0 1.9608% MA 456.96 0.4639%

Hologic Inc

Healthcare US HOLX


Last update at 2024-06-24T20:00:00Z

Day Range


52 Week Range



  • Previous Close 73.07
  • Market Cap17120.54M
  • Volume997364
  • P/E Ratio38.01
  • Dividend Yield-%
  • EBITDA1222.10M
  • Revenue TTM3960.60M
  • Revenue Per Share TTM16.39
  • Gross Profit TTM 2481.40M
  • Diluted EPS TTM1.93


Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax 676.10M 1588.20M 2361.10M 1001.90M -95.30000M
Minority interest - 0.00000M 1.80M -4.70000M 2.10M
Net income 456.00M 1302.00M 1871.50M 1115.20M -40.20000M
Selling general administrative 392.40M 407.70M 433.20M 356.00M 332.30M
Selling and marketing expenses 595.20M 630.30M 561.20M 484.60M 564.90M
Gross profit 2071.50M 2997.40M 3795.80M 2227.50M 1308.10M
Reconciled depreciation 323.40M 430.10M 406.90M 376.00M 463.10M
Ebit 880.30M 1640.20M 2480.30M 1105.00M 134.40M
Ebitda 1203.70M 2104.70M 2885.80M 1514.10M 597.50M
Depreciation and amortization 323.40M 464.50M 405.50M 409.10M 463.10M
Non operating income net other - 43.10M -25.60000M 13.40M -
Operating income 668.40M 1640.20M 2480.30M 1105.00M 134.40M
Other operating expenses 3268.90M 3232.00M 3149.40M 2651.70M 3240.60M
Interest expense 111.10M 95.10M 93.60M 116.50M 140.80M
Tax provision 220.10M 286.20M 491.40M -108.60000M -54.10000M
Interest income 120.50M 12.90M 1.40M 4.30M 4.60M
Net interest income 9.40M -82.20000M -92.20000M -112.20000M -136.20000M
Extraordinary items - - - - -5.00000M
Non recurring - 30.10M 9.30M 19.70M -
Other items - - - - -
Income tax expense 220.10M 286.20M 491.40M -108.60000M -55.10000M
Total revenue 4030.40M 4862.80M 5632.30M 3776.40M 3367.30M
Total operating expenses 1310.00M 1366.60M 1312.90M 1102.80M 1181.40M
Cost of revenue 1958.90M 1865.40M 1836.50M 1548.90M 2059.20M
Total other income expense net -94.80000M -52.00000M -119.20000M -103.10000M -229.70000M
Discontinued operations - - - - -
Net income from continuing ops 456.00M 1302.00M 1869.70M 1110.50M -203.60000M
Net income applicable to common shares - 1302.00M 1871.50M 1115.20M -203.60000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 9139.30M 9071.20M 8919.90M 7195.80M 6611.10M
Intangible assets 888.60M 1280.60M 1659.20M 1307.50M 1459.80M
Earning assets - - - - -
Other current assets 206.90M 281.20M 554.50M 97.30M 97.20M
Total liab 4122.40M 4195.00M 4701.30M 4488.50M 4332.00M
Total stockholder equity 5016.90M 4876.20M 4218.60M 2705.20M 2279.10M
Deferred long term liab - 100.20M 270.80M 214.70M -
Other current liab 8.20M 538.50M 599.90M 549.50M 432.70M
Common stock 3.00M 3.00M 3.00M 2.90M 2.90M
Capital stock - 3.00M 3.00M 2.90M 2.90M
Retained earnings 2056.30M 1600.30M 298.30M -1573.20000M -2688.70000M
Other liab - 448.90M 662.30M 429.30M 419.80M
Good will 3281.30M 3236.50M 3281.60M 2657.90M 2563.70M
Other assets - 210.50M 245.70M 424.50M 95.80M
Cash 2722.50M 2339.50M 1170.30M 701.00M 601.80M
Cash and equivalents - - - - -
Total current liabilities 1207.30M 937.70M 1326.80M 1239.30M 1070.10M
Current deferred revenue 199.20M 186.50M 198.00M 186.10M 179.50M
Net debt 95.70M 483.90M 1854.90M 2337.80M 2453.20M
Short term debt 287.00M 15.00M 313.00M 324.90M 271.40M
Short long term debt 287.00M 15.00M 313.00M 324.90M 271.40M
Short long term debt total 2818.20M 2823.40M 3025.20M 3038.80M 3055.00M
Other stockholder equity 3105.20M 3511.10M 3976.40M 4325.20M 5007.20M
Property plant equipment - 481.60M 564.70M 491.50M 470.90M
Total current assets 4184.50M 3862.00M 3168.70M 2222.30M 1792.60M
Long term investments - 5.50M 9.50M 11.40M 54.10M
Net tangible assets - 359.10M -722.20000M -1260.20000M -1907.80000M
Short term investments - - - - -
Net receivables 625.60M 617.60M 942.70M 1028.90M 648.70M
Long term debt 2531.20M 2808.40M 2712.20M 2713.90M 2783.60M
Inventory 617.60M 623.70M 501.20M 395.10M 444.90M
Accounts payable 712.90M 197.70M 215.90M 178.80M 186.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - 2.10M -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -147.60000M -238.20000M -59.10000M -49.70000M -42.30000M
Additional paid in capital - - - - -
Common stock total equity - 3.00M 3.00M 2.90M 2.90M
Preferred stock total equity - - - - -
Retained earnings total equity - 1600.30M 298.30M -1573.20000M -
Treasury stock - -2531.50000M -1989.40000M -1579.60000M -926.00000M
Accumulated amortization - - - - -
Non currrent assets other 267.90M 188.80M 214.30M 489.70M 90.30M
Deferred long term asset charges - - - - -
Non current assets total 4954.80M 5209.20M 5751.20M 4973.50M 4818.50M
Capital lease obligations - 98.20M 119.40M 17.40M 54.70M
Long term debt total - 2808.40M 2712.20M 2731.30M 2802.80M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments -152.10000M -206.30000M -1329.60000M -141.60000M -280.70000M
Change to liabilities -8.60000M -26.70000M 34.40M 106.10M 8.90M
Total cashflows from investing activities -152.10000M -206.30000M -1329.60000M -141.60000M -280.70000M
Net borrowings -19.00000M -212.30000M -113.40000M -23.20000M -257.70000M
Total cash from financing activities -483.20000M -756.00000M -529.80000M -659.90000M -431.50000M
Change to operating activities 9.40M 368.50M -61.20000M -190.20000M -22.50000M
Net income 456.00M 1302.00M 1869.70M 1110.50M -40.20000M
Change in cash 416.20M 1169.20M 469.30M 99.20M -64.90000M
Begin period cash flow 2339.50M 1170.30M 701.00M 601.80M 666.70M
End period cash flow 2755.70M 2339.50M 1170.30M 701.00M 601.80M
Total cash from operating activities 1051.20M 2125.70M 2330.40M 896.60M 649.50M
Issuance of capital stock - - - - -
Depreciation 323.40M 430.10M 406.90M 376.00M 463.10M
Other cashflows from investing activities 13.10M 79.50M -2.20000M -43.30000M -35.30000M
Dividends paid - - 51.30M 65.60M 49.80M
Change to inventory -4.90000M -136.60000M -84.10000M -25.30000M -63.00000M
Change to account receivables -1.50000M 272.30M 110.90M -427.10000M -76.50000M
Sale purchase of stock -474.80000M -542.10000M -409.70000M -653.60000M -200.10000M
Other cashflows from financing activities -32.40000M 1438.30M 1249.60M 791.20M 2049.30M
Change to netincome 260.00M -60.60000M 39.00M 16.20M 546.30M
Capital expenditures 150.20M 127.20M 162.70M 156.40M 113.60M
Change receivables - 272.30M 110.90M -427.10000M -
Cash flows other operating - 406.10M -43.30000M -259.80000M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 1163.40M 471.00M 95.10M -
Change in working capital 11.80M 454.20M 13.00M -636.30000M -161.30000M
Stock based compensation 79.60M 66.70M 65.00M 83.30M 62.00M
Other non cash items 289.50M 38.90M 45.90M 57.50M 557.60M
Free cash flow 901.00M 1998.50M 2167.70M 740.20M 535.90M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Hologic Inc
-0.59 0.81% 72.48 38.01 19.12 4.57 3.90 4.74 17.68
Intuitive Surgical Inc
-3.52 0.81% 429.04 73.05 61.73 19.15 10.25 18.41 59.92
Essilor International SA
0.23 0.21% 111.94 35.39 24.81 3.63 2.20 4.00 16.25
EssilorLuxottica Société anonyme
-3.33 1.47% 223.25 35.71 25.13 3.62 2.23 4.00 16.25
Becton Dickinson and Company
-2.38 1.00% 235.91 47.65 17.51 3.60 2.69 4.33 19.06

Reports Covered

Stock Research & News


Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Hologic Inc

250 Campus Drive, Marlborough, MA, United States, 01752

Key Executives

Name Title Year Born
Mr. Stephen P. MacMillan Chairman, CEO & Pres 1964
Ms. Karleen M. Oberton Chief Financial Officer 1971
Mr. John M. Griffin Gen. Counsel 1961
Mr. Kevin R. Thornal Group Pres of Global Diagnostic Solutions 1974
Mr. Paul Malenchini Chief Information Officer NA
Ryan M. Simon VP of Investor Relations NA
Ms. Elisabeth A. Hellmann Sr. VP of Global HR & Corp. Communications 1969
Mr. Jan Verstreken Group Pres of International 1968
Ms. Monica Aguirre Berthelot VP & Chief of Staff NA
Mr. Mike Kelly Chief Supply Chain Officer and Corp. VP of Quality Assurance & Regulatory Affairs NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).